Question: What do a big-box electronics retailer, a cheap-chic discounter and the biggest construction company around have in common?
Top 5 Communications Equipment Companies To Watch For 2015: CEVA Inc.(CEVA)
CEVA, Inc., together with its subsidiaries, engages in licensing silicon intellectual property (SIP) for the handsets, mobile broadband, portable, and consumer electronics markets primarily in the United States, Europe, the Middle East, and the Asia Pacific. It designs and licenses DSP cores in the form of a hardware description language definition; a portfolio of application-specific platforms, including wireless baseband, audio, imaging and vision, voice over Internet protocols (VoIP), Bluetooth, and serial storage technology and serial attached SCSI; and development platforms, software development kits, and software debug tools that facilitate system design, debug, and software development. The company?s intellectual property (IP) is used by semiconductor and original equipment manufacturer companies for application-specific integrated circuits and application-specific standard products. It serves various markets, including feature phones, smartphones, machine to machi ne for various cellular standards, home entertainment, portable game consoles, and serial storage and telecommunication devices. CEVA, Inc. markets its technology through a direct sales force. The company was formerly known as ParthusCeva, Inc. and changed its name to CEVA, Inc. in December 2003. CEVA, Inc. was founded in 1999 and is headquartered in Mountain View, California.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on CEVA (Nasdaq: CEVA ) , whose recent revenue and earnings are plotted below.
Top 10 Railroad Stocks To Watch Right Now: Ashley(l)
Laura Ashley Holdings plc, together with its subsidiaries, engages in the design, manufacture, sourcing, distribution, sale, and licensing of clothing, accessories, and home furnishings in the United Kingdom and internationally. It offers various furniture products, including beds, upholstered furniture, mirrors, and cabinet furniture; home accessories, such as lighting products, gifts, bed linen, rugs, throws, cushions, and children?s accessories; and decorative products comprising curtains, blinds, fabrics, paints, decorative accessories, and wall coverings. The company also offers fashion products, such as clothing that include dresses, knitwear, tops, blouses, skirts, trousers, leggings, coats, jackets, swimwear, and shoes, as well as accessories comprising bags, purses, jewellery, and scarves. In addition, it provides design services for homes; and licenses various products, such as stationery, wooden flooring, blinds, interior window shutters, carpets, nursery produ cts, fireplaces, garden products, eyewear, tiles, promotional gifting, toiletries, shoes, and Fairtrade clothing. The company sells its products through retail stores, online, and mail order. As of January 29, 2011, it operated 217 stores, including 138 mixed product stores, 55 home stores, 22 home concession stores, 1 gifts and accessories store, and 1 clearance outlet in the United Kingdom; and 240 franchised stores in 29 countries. The company is based in London, the United Kingdom.
Advisors' Opinion:- [By Robert Rapier]
Meanwhile, sponsor�Loews�(NYSE: L) has added to the cash drain by converting its class B units into common that will cost Boardwalk an additional $25 million in distributions annually. The Bluegrass Pipeline Boardwalk is marketing in a partnership with Williams (NYSE: WMB) is looking more and more as a defensive measure to replace lost business than as a path to future glory. And it now faces competition that could drive expected returns lower.
Top 10 Railroad Stocks To Watch Right Now: Synovus Financial Corp.(SNV)
Synovus Financial Corp., a diversified financial services and bank holding company, provides commercial and retail banking, financial management, insurance, and mortgage services in Georgia, Alabama, South Carolina, Florida, and Tennessee. Its retail banking services include accepting customary types of demand and savings deposits; mortgage, installment, and other retail loans; investment and brokerage services; safe deposit services; automated banking services; automated fund transfers; Internet based banking services; and bank credit card services, including mastercard and visa services. The company?s commercial banking services comprise cash management and asset management services, capital markets services, and institutional trust services, as well as commercial, financial, and real estate loans. It also provides various other financial services, which include the portfolio management for fixed-income securities, investment banking, the execution of securities transac tions as a broker/dealer, and the provision of individual investment advice on equity and other securities; trust services; mortgage services; and financial planning services. Synovus Financial Corp. was founded in 1888 and is headquartered in Columbus, Georgia.
Advisors' Opinion:- [By Robert Eberhard]
Synovus Financial (NYSE: SNV ) throws its hat into the earnings ring early Tuesday, and investors are facing a big question: Will CEO Kessel D. Stelling and crew deliver good news? Or should investors be wary of less than impressive results?
- [By Amanda Alix]
Large regional bank Synovus Financial (NYSE: SNV ) has released its second-quarter earnings report, a week earlier�than previously stated. The report contained much good news for the troubled bank, but the early release was likely timed to coincide with an exciting announcement: The bank also revealed that it has a plan to finally repay its nearly $1 billion portion�of Troubled Asset Relief Program funds.
Top 10 Railroad Stocks To Watch Right Now: Chimerix Inc (CMRX)
Chimerix, Inc., incorporated on April, 07, 2000, is a biopharmaceutical company committed to the discovery, development and commercialization of novel, oral antiviral therapeutics that are designed to transform patient care in areas of high unmet medical need. Its lipid technology has given rise to two clinical-stage compounds, CMX001 and CMX157, which have demonstrated the potential for enhanced antiviral activity and safety in convenient, orally administered dosing regimens.
CMX001 is an orally administered drug that utilizes its lipid technology to deliver intracellular concentrations of a potent antiviral compound, cidofovir-diphosphate (CDV-PP). Following oral dosing, CMX001 is absorbed through the gut, remains intact in the plasma, and is readily taken up by and delivered into cells. Once inside cells, CMX001 is converted into CDV-PP, which acts as an alternative substrate in a replicating virus. CMX001 is similar to the drug cidofovir in that both drugs are converted into CDV-PP once inside cells. Although cidofovir is approved for administration in an intravenous formulation, Vistide, it requires a plasma concentration to deliver a therapeutic level of cidofovir into cells and its use is limited due to the risk of kidney damage.
CMX157, Its second clinical stage compound, is an oral nucleotide compound in Phase 1 development for the treatment of human immunodeficiency virus (HIV) infection. In July 2012, the Company granted Merck an exclusive worldwide license to develop and commercialize CMX157 for all human uses. Merck is responsible for all development and marketing activities for CMX157 on a worldwide basis.
Advisors' Opinion:- [By Ben Levisohn]
Biotech companies that are most likely to benefit because they are “Ahead in clinical development and/or have established relationships with [the Biomedical Advanced Research and Development Authority, or] BARDA which may facilitate getting a contract” include GlaxoSmithKline (GSK), NewLink Genetics (NLNK), Johnson & Johnson (JNJ) and Chimerix (CMRX). Kantor includes Tekmira�(TKMR) and Sarepta (SRPT) among “companies with viable programs” that are “moving forward and likely to attract additional funding.”
Top 10 Railroad Stocks To Watch Right Now: Strategic Diagnostics Inc.(SDIX)
Strategic Diagnostics Inc., a biotechnology company, develops, commercializes, and markets proprietary products, services, and solutions for the pharmaceutical, biotechnology, diagnostics, food safety, and environmental markets. Its life science portfolio includes products and custom services that supply critical reagents used across the life science research and development markets. These products and services include custom antibodies, in-vitro diagnostic-grade antibodies, proprietary critical reagent products, associated bio-processing services, and custom assay design and development services that are sold to pharmaceutical, biotechnology, and diagnostic companies, as well as to biomedical research centers. The company also provides Kit products, including immunoassays, which represent advanced technology for the detection of food pathogens and soil contaminants. Its detection technologies allow industrial customers to identify the presence of adulterants, such as chem ical toxins, biological pathogens, and other contaminants, which can compromise human or environmental safety, and/or impact efficiencies of production processes. These products are used in various applications, including food and beverage manufacturing, environmental management, and agriculture and agro-science. The company markets and sells its products in the life sciences, and food safety product categories through a direct sales force, Internet, and a network of distributors, as well as through its corporate partners in the United States, Canada, Mexico, Latin America, Europe, and Asia. Strategic Diagnostics Inc. was founded in 1987 and is headquartered in Newark, Delaware.
Advisors' Opinion:- [By CRWE]
SDIX (Nasdaq:SDIX) – a leading provider of biotechnology-based products and services for a broad range of life science, biotechnology, diagnostic, and food safety applications, expects to release its second quarter 2012 results at approximately 4 p.m. ET on Wednesday, August 8, 2012.
Top 10 Railroad Stocks To Watch Right Now: Mandalay Digital Group Inc (MNDL)
Mandalay Digital Group, Inc., incorporated on September 14, 2007, through its wholly owned subsidiary, Digital Turbine, provides mobile solutions for wireless carriers globally to enable them to monetize mobile content. The Company's products include mobile application management through DT Ignite, user experience and discovery through DT IQ, application stores and content through DT Marketplace, and content management and mobile payments through DT Pay.
The Company delivers a mobile services platform that works with mobile operators and third-party publishers to provide portal management, user interface, content development and billing technology that enables the responsible distribution of mobile entertainment. Its Digital Turbine delivers end-to-end products and solutions to mobile operators, including Vodafone, Telefonica, Turkcell, Telecom Italia, SingTel, Smart, Telstra, Cricket and Singtel Optus. Its mobile services platform and billing technology enables mobile operators, original equipment manufacturers (OEMs) and third-parties to manage their content portals and storefronts.
Advisors' Opinion:- [By Monica Gerson]
Mandalay Digital Group (NASDAQ: MNDL) is projected to post a Q4 loss at $0.11 per share on revenue of $6.98 million.
Advanced Photonix (NYSE: API) is expected to post a Q4 loss at $0.01 per share on revenue of $7.04 million.
Top 10 Railroad Stocks To Watch Right Now: Acura Pharmaceuticals Inc.(ACUR)
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion and Impede technologies. Its Aversion Technology is a proprietary platform technology providing abuse deterrent features and benefits to orally administered pharmaceutical drug products containing abusable active ingredients, such as tranquillizers, stimulants, sedatives, and decongestants. The company offers OXECTA Tablets CII, which are oral formulations of oxycodone HCl for the management of acute and chronic moderate to severe pain; and Impede PSE, a pseudoephedrine hydrochloride tablet product candidate. It is also developing opioid analgesic product candidates, which would be used to relieve pain while discouraging common methods of opioid product misuse and abuse, including intravenous injection of dissolved tablets or capsules; nasal snorting of crushed tablets or capsules; and intentional swallowing of excess quantities of tablets or capsules. In addition, the company investigates and develops mechanisms to incorporate abuse deterrent features into abused and misused pharmaceutical products using its Impede Technology. Acura Pharmaceuticals, Inc. has a license, development, and commercialization agreement with King Pharmaceuticals Research and Development, Inc. to develop and commercialize certain opioid analgesic products utilizing the company?s proprietary Aversion Technology in the United States, Canada, and Mexico. The company was founded in 1935 and is based in Palatine, Illinois.
Advisors' Opinion:- [By Sean Williams]
ALKS-7106 for the treatment of pain has big potential as it encompasses a broad audience, but it'll need to overcome the common stigma of pain drugs with regard to easy abuse potential. According to the press release, Alkermes will be introducing newer technology that will make its opioid-based drug more resistant to abuse. It should be curious to see how well this performs as there aren't many successful abuse-resistant drugs, or companies developing those drugs for that matter. Acura Pharmaceuticals (NASDAQ: ACUR ) , for instance, successfully brought moderate-to-severe painkiller Oxecta to market in 2011 (which it subsequently licensed to Pfizer) and a bioequivalent version of decongestant pseudoephedrine to market last year, but sales of neither drug has exactly taken off. Like with its MMF prodrug, Alkermes anticipates a mid-2014 clinical trial launch date.
- [By Rick Munarriz]
Thursday
Acura Pharmaceuticas (NASDAQ: ACUR ) checks in on Thursday. Drugmakers use Acura's Aversion and Impede technologies to create abuse-deterrent treatments. In short, if an abuser tries to extract the active ingredient of a drug to heighten addictive experiences, Acura's technologies kick in to make the whole dose unusable. - [By John Udovich]
On Tuesday, small cap specialty pharmaceutical company�Acura Pharmaceuticals, Inc (NASDAQ: ACUR) surged 27.52% to $1.90 on no apparent news beyond a speculative Seeking Alpha article that talked about certain catalysts����meaning its worth taking a closer look at the company to see what�� going on and whether shares could move higher.�
- [By James E. Brumley]
What do Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) and CytRx Corporation (NASDAQ:CYTR) have in common? Yes, they're both biotech stocks, though that's not the most relevant answer right now. The best answer regarding the commonality between CYTR and ACUR at this point is that both are actionable, even of for totally different reasons/totally different directions. A closer look at each is merited.
No comments:
Post a Comment